Trial · NCT02996500
Results by group746
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 746
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in the Simplified Disease Activity Index (SDAI) at Week 12 | Placebo | -13.87 | 95% Confidence Interval -17.70 to -10.02 | units on a scale | |
| Change From Baseline in the Simplified Disease Activity Index (SDAI) at Week 12 | PF-06650833 20 mg | -21.71 | 95% Confidence Interval -26.14 to -17.20 | units on a scale | |
| Change From Baseline in the Simplified Disease Activity Index (SDAI) at Week 12 | PF-06650833 60 mg | -22.83 | 95% Confidence Interval -26.57 to -19.20 | units on a scale | |
| Change From Baseline in the Simplified Disease Activity Index (SDAI) at Week 12 | PF-06650833 200 mg | -24.77 | 95% Confidence Interval -28.54 to -21.08 | units on a scale | |
| Change From Baseline in the Simplified Disease Activity Index (SDAI) at Week 12 | PF-06650833 400 mg | -25.16 | 95% Confidence Interval -28.85 to -21.39 | units on a scale | |
| Change From Baseline in SDAI at Weeks 4 and 8 | Placebo | Week 4 | -10.78 | 95% Confidence Interval -15.07 to -6.49 | units on a scale |
| Change From Baseline in SDAI at Weeks 4 and 8 | PF-06650833 20 mg | Week 4 | -12.39 | 95% Confidence Interval -14.68 to -10.10 | units on a scale |
| Change From Baseline in SDAI at Weeks 4 and 8 | PF-06650833 60 mg | Week 4 | -14.29 | 95% Confidence Interval -16.87 to -11.71 | units on a scale |
| Change From Baseline in SDAI at Weeks 4 and 8 | PF-06650833 200 mg | Week 4 | -13.56 | 95% Confidence Interval -17.25 to -9.86 | units on a scale |
| Change From Baseline in SDAI at Weeks 4 and 8 | PF-06650833 400 mg | Week 4 | -12.30 | 95% Confidence Interval -15.46 to -9.14 | units on a scale |
| Change From Baseline in SDAI at Weeks 4 and 8 | Placebo | Week 8 | -17.07 | 95% Confidence Interval -22.58 to -11.55 | units on a scale |
| Change From Baseline in SDAI at Weeks 4 and 8 | PF-06650833 20 mg | Week 8 | -16.62 | 95% Confidence Interval -20.71 to -12.53 | units on a scale |
| Change From Baseline in SDAI at Weeks 4 and 8 | PF-06650833 60 mg | Week 8 | -18.85 | 95% Confidence Interval -22.03 to -15.67 | units on a scale |
| Change From Baseline in SDAI at Weeks 4 and 8 | PF-06650833 200 mg | Week 8 | -19.95 | 95% Confidence Interval -24.81 to -15.08 | units on a scale |
| Change From Baseline in SDAI at Weeks 4 and 8 | PF-06650833 400 mg | Week 8 | -21.15 | 95% Confidence Interval -25.50 to -16.79 | units on a scale |
| Percentage of Participants With SDAI Low Disease Activity Score (LDAS) (SDAI <=11) at 4, 8, and 12 Weeks | Placebo | Week 4 | 8.1 | 95% Confidence Interval 0.0 to 16.9 | percentage of participants |
| Percentage of Participants With SDAI Low Disease Activity Score (LDAS) (SDAI <=11) at 4, 8, and 12 Weeks | PF-06650833 20 mg | Week 4 | 7.9 | 95% Confidence Interval 0.0 to 16.5 | percentage of participants |
| Percentage of Participants With SDAI Low Disease Activity Score (LDAS) (SDAI <=11) at 4, 8, and 12 Weeks | PF-06650833 60 mg | Week 4 | 12.2 | 95% Confidence Interval 3.1 to 21.4 | percentage of participants |
| Percentage of Participants With SDAI Low Disease Activity Score (LDAS) (SDAI <=11) at 4, 8, and 12 Weeks | PF-06650833 200 mg | Week 4 | 10.6 | 95% Confidence Interval 1.8 to 19.5 | percentage of participants |
| Percentage of Participants With SDAI Low Disease Activity Score (LDAS) (SDAI <=11) at 4, 8, and 12 Weeks | PF-06650833 400 mg | Week 4 | 8.5 | 95% Confidence Interval 0.5 to 16.5 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02996500/results